BayOmics is a high-tech R&D company that focuses on proteomics. The company has recently completed a Pre-A round of financing in the tens of millions of RMB. This round was led by Qiming Venture Capital, with participation from CICC Capital's funds and angel round shareholder GL Ventures. In the future, BayOmics will be based on the Greater Bay Area and aims to play a significant role in the entire pipeline of innovative markers and drug target discovery.

Recently, BayOmics launched a spatially visualized proteomic whole process solution. With the patented SISPROT technology, qualitative and quantitative analysis of tissue microenvironment imaging and protein expression can be realized at specific spatial locations in pathological sections. The technology also enables cell identification, dissection, sample preparation and data analysis with single-cell resolution. With its detection sensitivity, over 7,000 proteins can be successfully identified in 0.1 mm² FFPE sections.

Recently, BayOmics innovatively launched the SISPROT kit. This technology is based on the company's proprietary patented technology that integrates all proteomic sample preparation steps into a single device, which significantly reduces the total operating time while minimizing sample loss and meeting the requirements of ultralow sample amounts. We are now sincerely recruiting national agents; please feel free to contact us by phone or email for inquiries.